Who is sponsoring NCT00195104?

NCT00195104 is sponsored by Weill Medical College of Cornell University.

What drugs are being tested in NCT00195104?

Interventions in NCT00195104: Arsenic Trioxide (Tricenox), Cytarabine.

What condition does NCT00195104 study?

NCT00195104 studies Myelodysplastic Syndrome.

Is NCT00195104 still recruiting?

NCT00195104 is currently completed. Last updated 3 March 2017.

Last reviewed 2017-03-03 · How we verify

NCT00195104

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Arsenic Trioxide in Combination With Cytarabine in Patients With High-risk MDS and Poor-prognosis AML

Completed Phase 1, PHASE2 Last updated 3 March 2017

What this trial tests

Phase 1, PHASE2 trial testing Arsenic Trioxide (Tricenox) in Myelodysplastic Syndrome in 87 participants. Completed in 20 June 2006.

Timeline

17 September 2003

Primary endpoint
17 March 2006

20 June 2006

Quick facts

Lead sponsor	Weill Medical College of Cornell University
Phase	Phase 1, PHASE2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	87
Start date	17 September 2003
Primary completion	17 March 2006
Estimated completion	20 June 2006
Sites	1 location across United States

Drugs / interventions tested

Arsenic Trioxide (Tricenox) — full drug profile →
Cytarabine — full drug profile →

Conditions studied

Myelodysplastic Syndrome — all drugs for Myelodysplastic Syndrome →

Sponsor

Weill Medical College of Cornell University

Who can join

18 and older, any sex, with Myelodysplastic Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to find out the effectiveness and side effects of arsenic trioxide in combination with low-dose ara-C.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Redox control of leukemia: from molecular mechanisms to therapeutic opportunities.
Irwin ME, Rivera-Del Valle N, Chandra J. · · 2013 · cited 111× · PMID 22900756 · DOI 10.1089/ars.2011.4258

Verify or expand the search:

Other recruiting trials for Myelodysplastic Syndrome

Currently open trials in the same condition.

NCT07020533 — A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Pa · Phase 1 · recruiting
NCT07422480 — A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myel · Phase 3 · recruiting
NCT07107126 — Safety and Proof-of-Concept Study of RPT1G in Adults With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndromes · Phase 1 · recruiting
NCT06781099 — Feasibility Trial of Extracorporeal Iron Purification in Patients With Myelodysplastic Syndrome or Myelofibrosis · NA · recruiting
NCT07285044 — The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Tr · Phase 2 · recruiting

Other Weill Medical College of Cornell University trials

Trials by the same sponsor.

NCT07485712 — Center for Research and Education on Aging and Technology Enhancement - CREATE V - Project 2 · NA · not yet recruiting
NCT05811338 — Center for Research and Education on Aging and Technology Enhancement - CREATE V - Project 1 · NA · not yet recruiting
NCT06118983 — Improving TRansitions ANd OutcomeS for Heart FailurE Patients in Home Health CaRe (I-TRANSFER-HF) · NA · recruiting
NCT06818734 — Implementation of a Clinical Decision Support Tool for Postpartum Depression · NA · not yet recruiting
NCT07485725 — Center for Research and Education on Aging and Technology Enhancement - CREATE V - Project 3 · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00195104 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Weill Medical College of Cornell University
Last refreshed: 3 March 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00195104.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing